Immunoassay for trypsinogen-4.

Bile Immunoassay PRSS3 Primary sclerosing cholangitis Trypsin Trypsinogen-4

Journal

Analytical biochemistry
ISSN: 1096-0309
Titre abrégé: Anal Biochem
Pays: United States
ID NLM: 0370535

Informations de publication

Date de publication:
01 07 2022
Historique:
received: 18 02 2022
revised: 30 03 2022
accepted: 01 04 2022
pubmed: 14 4 2022
medline: 11 5 2022
entrez: 13 4 2022
Statut: ppublish

Résumé

Trypsin has been identified as a pancreatic protease comprising three isoenzymes, trypsin-1, -2, and -3. However, the gene for trypsinogen-3, PRSS3, also gives rise to additional variants, trypsinogen-4A and B, which differ from trypsinogen-3 only with respect to the leader-peptide part, and when activated are identical to trypsin-3. The unique overlapping leader peptides of trypsinogen-4A and B allowed us to develop a specific sandwich-type immunofluorometric assay that detects both these isoforms, but not trypsinogen-3 or activated trypsinogen-4. We measured the concentrations of trypsinogen-4 in various cell line lysates and bile of primary sclerosing cholangitis patients. Lysates of cell lines MDA-MB-231 and PC-3, and astrocytes contained trypsinogen-4, while the conditioned media from these cells did not, suggesting that trypsinogen-4, lacking a classical signal sequence, is not secreted from the cells. Interestingly, 5.7% of the 212 bile samples analyzed contained measurable (>2.4 μg/l) trypsinogen-4. In conclusion, we have established a specific assay for trypsinogen-4 and demonstrated that trypsinogen-4 can be found in biological samples. However, the clinical utility of the assay remains to be established.

Identifiants

pubmed: 35417678
pii: S0003-2697(22)00137-3
doi: 10.1016/j.ab.2022.114681
pii:
doi:

Substances chimiques

Isoenzymes 0
Trypsinogen 9002-08-8
PRSS3 protein, human EC 3.4.21.4
Trypsin EC 3.4.21.4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

114681

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Hannu Koistinen (H)

Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: hannu.k.koistinen@helsinki.fi.

Riitta Koistinen (R)

Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Kristina Hotakainen (K)

Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Anna Lempiäinen (A)

Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Kalle Jokelainen (K)

Department of Gastroenterology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Martti Färkkilä (M)

Department of Gastroenterology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Ulf-Håkan Stenman (UH)

Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH